Ibrutinib Plus Prednisone Does Not Improve Response Rates in cGVHD
February 2nd 2023First-line ibrutinib plus prednisone missed the primary endpoint in the phase 3 iNTEGRATE trial by not improving the response rate in patients with chronic graft-versus-host-disease compared with placebo plus prednisone.
During End-of-Life Cancer Care, Patients of Color Less Likely To Receive Opioid Treatment
January 14th 2023Findings showed that Black patients were 4.3 percentage points less likely to receive any opioid and 3.1 percentage points less likely to receive long-acting opioids near end-of-life compared with White patients.
Distress in Advanced Cancer May Be Alleviated With Psychedelic-Assisted Psychotherapy
November 15th 2022Psychiatric distress and existential distress are associated with poor outcomes in patients with advanced cancers and treatment options such as psychotherapy have demonstrated limited effectiveness.
Improvements in Accessibility to Cancer Screenings Are Needed for Individuals With Disabilities
November 2nd 2022It is imperative that nurses and other health care professionals not only recognize the disparities in preventive screenings but become part of the solution. Early detection and cancer treatment must be accessible for those with disabilities, as it can help save lives.